Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.59 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | WDR5 | P61964 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25976163 | 0.99 | USP2 (0.63) | ALDH1A1USP2HPGDERCC1ERCC4 | |
| SCHEMBL4035763 | 0.87 | ALDH1A1 (0.60) | ALDH1A1USP2HPGDERCC1ERCC4 | |
| SCHEMBL23207605 | 0.86 | MAPT (0.54) | ALDH1A1USP2HPGDERCC1ERCC4 | |
| SCHEMBL13039162 | 0.86 | SMN1; SMN2 (0.64) | ALDH1A1USP2HPGDERCC1ERCC4 | |
| SCHEMBL13746187 | 0.85 | MAPT (0.62) | ALDH1A1NPSR1MAPTMEN1KMT2A | |
| SCHEMBL26946203 | 0.84 | ALDH1A1 (0.50) | ALDH1A1USP2HPGDERCC1ERCC4 | |
| SCHEMBL5523329 | 0.83 | ALDH1A1 (0.61) | ALDH1A1USP2HPGDERCC1ERCC4 | |
| SCHEMBL5530350 | 0.82 | ALDH1A1 (0.72) | ALDH1A1KMT2ALMNA | |
| SCHEMBL12993457 | 0.82 | ALDH1A1 (0.57) | ALDH1A1USP2HPGDERCC1ERCC4 | |
| SCHEMBL5373226 | 0.82 | ALDH1A1 (0.52) | ALDH1A1USP2HPGDMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| EP-1523473-B1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | ALDH1A1 4067/4885USP2 2769/4885HPGD 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.